STILL NOT SAFE
Banking legislation left out of National Defense Authorization Act
Rep. Ed Perlmutter (D-CO) has stated he will be immediately working to attach banking legislation to pending omnibus appropriations legislation after it was not included in the National Defense Authorization Act (NDAA), reports Marijuana Moment.
The publication highlights that, while the bill could still advance this year, the path forward is unclear.
Perlmutter stated: “Though SAFE didn’t get done in the NDAA, we successfully elevated the issue and have everyone’s attention, so now we need to get it done. There is time to do it,”.
Legacy cultivators beginning to see government support
There is a global renaissance underway for the cannabis legacy farmer, with governments beginning to shape public policy to help them, writes Cannabis Business Times.
The publication highlights that legacy farmers are proving to be an enduring competition for the regulated and certified market, noting that:
– 43% of all American cannabis sales still go to the illicit market.
– Calculations based on total consumption and legal sales suggest that between 60% and 75% of the sales in California, for example, are not coming from the regulated legal sector of the industry but, rather, legacy farmers.
The publication explores the legacy market in the US, North America and Europe, stating that Germany could create a plethora of smaller-scale production as incoming legislation may allow both home cultivation and a recreational market sourced exclusively from domestic farmers.
EU CANNABIS
An entrepreneur’s guide to the recreational cannabis market in Europe
Michael Sassano, CEO of Somai Pharmaceuticals reflects on Q3 2022.
Writing for Cannabis Wealth, Sassano explores the changing cannabis policy landscape in Europe with a focus on Germany, noting that Moving forward with cannabis legalization isn’t just the will of German politicians but that it is also about European Union and United Nations rules.
Sassano writes: “Let’s see what the EU says before we pass judgment if Germany pivots to accepting sales from within the EU. There are no doubts Germany is starting a brush fire with cannabis legalization and that all eyes are on the EU rulings for these rules. Nothing is expected to be finalized until the end of 2023 at best.”
GLOBAL CANNABIS REPORT: 3RD EDITION
Global cannabis stocks significantly underperformed in 2022, but trend expected to ‘reverse’ in near future
According to Prohibition Partners’ The Global Cannabis Report: 3rd Edition the residual fallout from the pandemic and ongoing war in Ukraine have dragged global stock market prices down 25% this year, reports BussinessCann.
However, Prohibition Partners notes that this downward trend is expected to ‘reverse in the not-too-distant future’ as sales and profitability continue to improve across the globe.
BusinessCann explores the report, looking at:
- The markets, including cannabis stocks versus general stocks.
- Rising sales, including the quarterly operating income of 10 cannabis companies.
BusinessCann writes: “Prohibition Partners argues that the decline ‘should not be viewed strictly as a bad omen’, pointing out that volumes were still far higher than in 2020 and that an increasing number of players continued to make investments across Europe.”
Legacy cultivators beginning to see government support
There is a global renaissance underway for the cannabis legacy farmer, with governments beginning to shape public policy to help them, writes Cannabis Business Times.
The publication highlights that legacy farmers are proving to be an enduring competition for the regulated and certified market, noting that:
– 43% of all American cannabis sales still go to the illicit market.
– Calculations based on total consumption and legal sales suggest that between 60% and 75% of the sales in California, for example, are not coming from the regulated legal sector of the industry but, rather, legacy farmers.
The publication explores the legacy market in the US, North America and Europe, stating that Germany could create a plethora of smaller-scale production as incoming legislation may allow both home cultivation and a recreational market sourced exclusively from domestic farmers.
EU CANNABIS
An entrepreneur’s guide to the recreational cannabis market in Europe
Michael Sassano, CEO of Somai Pharmaceuticals reflects on Q3 2022.
Writing for Cannabis Wealth, Sassano explores the changing cannabis policy landscape in Europe with a focus on Germany, noting that Moving forward with cannabis legalization isn’t just the will of German politicians but that it is also about European Union and United Nations rules.
Sassano writes: “Let’s see what the EU says before we pass judgment if Germany pivots to accepting sales from within the EU. There are no doubts Germany is starting a brush fire with cannabis legalization and that all eyes are on the EU rulings for these rules. Nothing is expected to be finalized until the end of 2023 at best.”
GLOBAL CANNABIS REPORT: 3RD EDITION
Global cannabis stocks significantly underperformed in 2022, but trend expected to ‘reverse’ in near future
According to Prohibition Partners’ The Global Cannabis Report: 3rd Edition the residual fallout from the pandemic and ongoing war in Ukraine have dragged global stock market prices down 25% this year, reports BussinessCann.
However, Prohibition Partners notes that this downward trend is expected to ‘reverse in the not-too-distant future’ as sales and profitability continue to improve across the globe.
BusinessCann explores the report, looking at:
- The markets, including cannabis stocks versus general stocks.
- Rising sales, including the quarterly operating income of 10 cannabis companies.
BusinessCann writes: “Prohibition Partners argues that the decline ‘should not be viewed strictly as a bad omen’, pointing out that volumes were still far higher than in 2020 and that an increasing number of players continued to make investments across Europe.”
Legacy cultivators beginning to see government support
There is a global renaissance underway for the cannabis legacy farmer, with governments beginning to shape public policy to help them, writes Cannabis Business Times.
The publication highlights that legacy farmers are proving to be an enduring competition for the regulated and certified market, noting that:
– 43% of all American cannabis sales still go to the illicit market.
– Calculations based on total consumption and legal sales suggest that between 60% and 75% of the sales in California, for example, are not coming from the regulated legal sector of the industry but, rather, legacy farmers.
The publication explores the legacy market in the US, North America and Europe, stating that Germany could create a plethora of smaller-scale production as incoming legislation may allow both home cultivation and a recreational market sourced exclusively from domestic farmers.
EU CANNABIS
An entrepreneur’s guide to the recreational cannabis market in Europe
Michael Sassano, CEO of Somai Pharmaceuticals reflects on Q3 2022.
Writing for Cannabis Wealth, Sassano explores the changing cannabis policy landscape in Europe with a focus on Germany, noting that Moving forward with cannabis legalization isn’t just the will of German politicians but that it is also about European Union and United Nations rules.
Sassano writes: “Let’s see what the EU says before we pass judgment if Germany pivots to accepting sales from within the EU. There are no doubts Germany is starting a brush fire with cannabis legalization and that all eyes are on the EU rulings for these rules. Nothing is expected to be finalized until the end of 2023 at best.”
GLOBAL CANNABIS REPORT: 3RD EDITION
Global cannabis stocks significantly underperformed in 2022, but trend expected to ‘reverse’ in near future
According to Prohibition Partners’ The Global Cannabis Report: 3rd Edition the residual fallout from the pandemic and ongoing war in Ukraine have dragged global stock market prices down 25% this year, reports BussinessCann.
However, Prohibition Partners notes that this downward trend is expected to ‘reverse in the not-too-distant future’ as sales and profitability continue to improve across the globe.
BusinessCann explores the report, looking at:
- The markets, including cannabis stocks versus general stocks.
- Rising sales, including the quarterly operating income of 10 cannabis companies.
BusinessCann writes: “Prohibition Partners argues that the decline ‘should not be viewed strictly as a bad omen’, pointing out that volumes were still far higher than in 2020 and that an increasing number of players continued to make investments across Europe.”
Legacy cultivators beginning to see government support
There is a global renaissance underway for the cannabis legacy farmer, with governments beginning to shape public policy to help them, writes Cannabis Business Times.
The publication highlights that legacy farmers are proving to be an enduring competition for the regulated and certified market, noting that:
– 43% of all American cannabis sales still go to the illicit market.
– Calculations based on total consumption and legal sales suggest that between 60% and 75% of the sales in California, for example, are not coming from the regulated legal sector of the industry but, rather, legacy farmers.
The publication explores the legacy market in the US, North America and Europe, stating that Germany could create a plethora of smaller-scale production as incoming legislation may allow both home cultivation and a recreational market sourced exclusively from domestic farmers.
EU CANNABIS
An entrepreneur’s guide to the recreational cannabis market in Europe
Michael Sassano, CEO of Somai Pharmaceuticals reflects on Q3 2022.
Writing for Cannabis Wealth, Sassano explores the changing cannabis policy landscape in Europe with a focus on Germany, noting that Moving forward with cannabis legalization isn’t just the will of German politicians but that it is also about European Union and United Nations rules.
Sassano writes: “Let’s see what the EU says before we pass judgment if Germany pivots to accepting sales from within the EU. There are no doubts Germany is starting a brush fire with cannabis legalization and that all eyes are on the EU rulings for these rules. Nothing is expected to be finalized until the end of 2023 at best.”
GLOBAL CANNABIS REPORT: 3RD EDITION
Global cannabis stocks significantly underperformed in 2022, but trend expected to ‘reverse’ in near future
According to Prohibition Partners’ The Global Cannabis Report: 3rd Edition the residual fallout from the pandemic and ongoing war in Ukraine have dragged global stock market prices down 25% this year, reports BussinessCann.
However, Prohibition Partners notes that this downward trend is expected to ‘reverse in the not-too-distant future’ as sales and profitability continue to improve across the globe.
BusinessCann explores the report, looking at:
- The markets, including cannabis stocks versus general stocks.
- Rising sales, including the quarterly operating income of 10 cannabis companies.
BusinessCann writes: “Prohibition Partners argues that the decline ‘should not be viewed strictly as a bad omen’, pointing out that volumes were still far higher than in 2020 and that an increasing number of players continued to make investments across Europe.”
Related Posts
Related Posts
Curaleaf Completes $16m Acquisition of Northern Green Canada
Curaleaf has finalised its $16m acquisition of Canadian cannabis producer Northern Green Canada (NGC), helping the company secure its foothold...
This Is The ‘Last 4/20 That Cannabis Will Be Schedule I’ Drug Says Blumenauer, As He Pushes Its Election Importance
US Rep. Earl Blumenauer, founding co-chair of the Congressional Cannabis Caucus, said he believes Saturday was the ‘last 4/20 celebration...
